US FDA orders warning labels on GLP-1 drugs regarding risk of vision loss
- 1The US FDA announced that GLP-1 drugs must include warning labels regarding a potential link to NAION, a rare eye disease.
- 2The incidence rate of NAION among annual GLP-1 drug users was found to be 6.4 per 100,000 people.
- 330 million Americans use GLP-1 drugs to treat diabetes and obesity.
So what's the key point?
The US FDA has ordered warning labels on obesity treatments stating that vision loss is possible. This means 30 million patients using these drugs need to be cautious.
Source Fortune · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.